Already Registered? Log In Now
Not Registered?
Business Email:
Complete this form to enter the webcast.
Already Registered?
(* indicates required field)
Complete this form to enter the webcast.
(* indicates required field)
Business Email*:
First Name*:
Last Name*:
Title*:
Company Name*:
Street Address 1*:
Street Address 2:
City*:
State/Province*:
--
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
District of Columbia
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Postal Code*:
Country*:
--
Afghanistan
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, The Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libyan Arab Jamahiriya
Liechtenstein
Lithuania
Luxembourg
Macao
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Macedonia, Republic of
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French Part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch Part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan
Tajikistan
Tanzania, United Republic of
Thailand
Timor-leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States Minor Outlying Islands
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
Business Phone:
Which best describes your job function?:
--
Clinical Research
Commercial Operations
Commercialization
Compliance
Consultant
Contract Services
Corporate Management
Drug Safety
Engineering
Environmental
Finance
HR
IT
Lab Management
Legal
Managed Care
Manufacturing/Processing
Market Research
Marketing
Media Planning
Medical Affairs
Medicare/Medicaid
Meeting Planner
Other
Packaging
Patient Programs/Services
Pharmacy
Procurement
Project Management
QA/QC
R&D
Regulatory Affairs
Reimbursement
Sales Management
Scientific
Supply Chain
Technology Transfer
Trade/Sales
Validation
X-Outcomes
Which best describes your business/industry?:
--
Academic
Audit & Financial Advisory
Biopharma
Bio Pharmaceutical
Biotech
Consultant
Contract Manufacturing Organization (CMO)
Contract Research Organization (CRO)
Convention/Visitors Bureau
Data Management/Technology Provider
Diagnostics
DMC (Destination Management Company)
Food
Government
Health Plan/Payer
Hospital/Medical Centers
Hotel
Laboratory
Legal/Law Firm
Marketing/Creative Agency
Medical Device
Non Profit
PBM (Pharmacy Benefit Management)
Pharmaceutical
Retail Pharmacy
Solutions Provider
Third Party Meeting Manager
Wholesaler/Distributer
checked
Yes, please subscribe me to BioPharm International's free e-newsletters.
By registering for this event, you agree to MJH Life Sciences ®
Terms and Conditions
,
Privacy Policy
, and understand your data will be used by MJH and its affiliates for amongst other things, alerting you to other services or products that you maybe interested in, and may be shared with or sold to third parties for their use, including possible contact with you through email or other communications, consistent with their respective privacy policy. If you do not agree to have your data used in this way, please contact
info@mjhassoc.com
.
*Denotes required.
Accelerating High-Concentration Protein Drug Product Development Via the High-Throughput, and High-Quality WuXiHigh™ Platform
Thu, Feb 22, 2024 11:00 AM EST{LOCAL_TZ}
Event Overview:
Of the total commercially available monoclonal antibody (mAb) therapeutics on the market, approximately one third are considered high concentration drug products, with the highest protein concentration approved by the U.S. Food and Drug Administration (FDA) standing at 200 mg/mL. High concentration biopharmaceuticals have become a fast-growing class due to several advantages, especially for frequent or long-term administrations (e.g., chronic disease) that include lower volume delivery requirements, potentially greater therapeutic effect, and reduced cost of goods. In addition, high concentration formulations benefit subcutaneous (SC) administration if the drug products can be filled into a prefilled syringe (PFS) or autoinjector thus eliminating the need for professional health care practitioner or hospitalization and potential self-administration at home.
However, many challenges exist in both formulation and process development of high concentration drug products. The difficulties in developing these products are due to a myriad of protein-protein interactions that become more pronounced as protein concentrations increase. To provide a more efficient, and effective means of developing these high protein concentration products, the WuXiHigh
TM
platform was established by the WuXi Biologics Drug Product Development department to address these problems. The WuXiHigh proprietary platform, incorporates features such as novel viscosity reducers, synergistic excipient combinations, high-throughput formulation screening strategies, and computer-assisted formulation development that revolutionizes the development and manufacturing of biologics and biologic-device combination products with protein concentrations >100 mg/mL. To date, the WuXi Biologics’ WuXiHigh
TM
platform has provided high concentration formulation development and manufacturing solutions to over 70 projects (up to 200 mg/mL and across a wide range of viscosities) for various modalities (e.g., monoclonal and bispecific antibodies, fusion proteins and antibody drug conjugates).
This webinar will address the challenges of developing high protein concentration formulations and provide multiple cases studies utilizing the WuXiHigh platform that successfully overcome the obstacles associated with this growing product class.
Key Learning Objectives:
Challenges and solutions that pertain to the development of high concentration biologics
High-throughput strategies for high concentration drug product development
Cutting-edge technologies and case sharing to demonstrate the WuXiHigh
TM
platform’s capabilities
Who Should Attend:
Biopharmaceutical research and development scientists working on high concentration protein therapeutic formulations or involved in biologics drug product development.
Pharmaceutical industry decision-makers and investors interested in innovative technologies for biologic drug development.
Biotechnology and pharmaceutical conferences and event organizers searching for notable advancements and innovative solutions in biologics development.
Regulatory agencies and policymakers focused on the approval and safety of high concentration biopharmaceuticals.
Featured Speaker
Jeremy Guo
Senior Vice President and the Head of Drug Product Development (DPD) and the Clinical Drug Product (DP) manufacturing network
WuXi Biologics
Jeremy Guo,
Ph.D., is Senior Vice President and the head of drug product development (DPD) and the clinical drug product (DP) manufacturing network at WuXi Biologics. He has over 20 years of industry experience in formulation, process, and device development for biologics over a wide range of modalities including recombinant proteins at Amgen, Regeneron, and Pfizer. Jeremy received his Ph.D. from University of Utah and B.S. from University of Colorado.
Speaker’s Email:
jeremy_guo@wuxibiologics.com
For any technical questions please contact Kristina Dunphey:
kdunphey@mjhevents.com
FAQs and System Test
Outlook ❯
Google ❯